Both in Pharmaceuticals
Crescent Biopharma vs Monopar Therapeutics
Over the past year CBIO returned +22.7% and MNPR returned −2.4%; their daily moves had a correlation of 0.16.
CBIO +22.7% MNPR −2.4%Growth of $1, one year, split-adjusted
| Metric | CBIO | MNPR |
|---|---|---|
| Price | $14.59 | $79.67 |
| Market cap | $542.0M | $534.8M |
| Today | −1.15% | −0.41% |
| 1 month | −12.1% | −28.8% |
| 6 months | −20.6% | +45.4% |
| Year to date | +23.0% | +22.0% |
| 1 year | +18.7% | +5.0% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 45.6× | — |
| Net cash | $171.6M | $134.3M |
| Dividend yield | — | — |
| Volatility (60d) | 77.0% | 58.7% |
| Short % of float | 16.3% | 17.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).